Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S.

Economists saw “limited” risk to the pharmaceutical firm’s stock, despite some expected impact on Tylenol consumption.

President Donald Trump is set to speak today on how Tylenol may be linked to autism. Here's when, who makes Tylenol, and ...

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

Shares may be rising because investors expected the White House to announce stricter regulations on the medication, Citi ...

President Donald Trump created a potentially existential crisis for Tylenol maker Kenvue Inc. with just three words about the ...

Kenvue stock pares losses after Trump claims about Tylenol's link to autism. Citi analysts said there was a lack of new ...

Earlier this week, the Trump administration publicly warned of a possible link between prenatal Tylenol use and autism, ...

Kenvue shares rebounded after a sharp fall triggered by Donald Trump's unfounded claims linking Tylenol to autism. Trump ...

Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn’t offer fresh evidence that could ...